Providers

US health care faces massive shifts: rising ACA deductibles, federal health leadership shakeups, and major care gaps in women's health and dermatology.

A new training framework operationalizes brachytherapy competencies for soft tissue sarcoma, covering implant geometry, CT planning, dose optimization, toxicity management, and radiation safety.

The FDA approves Datroway for first-line metastatic triple-negative breast cancer in immunotherapy-ineligible patients.

This review will appear in the June issue of Evidence-Based Oncology.

From hypofractionation to proton beam therapy to pembrolizumab combinations, a new review details how 2025 reshaped the radiotherapy landscape for soft tissue sarcomas.

Breast cancer incidence climbs in young women under 40 and risk-based screening earlier may help reduce this, explains Rani Bansai, MD.

Texas Oncology boosts precision medicine with near-universal biomarker testing, quality measurement, and genomic insights—advancing health equity through streamlined workflows and coverage. This commentary will appear in the June issue of Evidence-Based Oncology.

Researchers found major differences between smoldering myeloma risk tools, raising concerns about overtreatment and defining “high risk.”

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk after, reshaping care.

Women’s Health Month highlights major 2026 shifts in menopause care, brain health, abortion access, doula coverage, and wearable tech.

Health updates cover abortion pill access, lung care research, pregnancy-linked heart risks, US longevity gaps, and flawed drug adherence metrics.

Prior authorization and payer hurdles delay prescription drugs; the Alliance for Patient Access urges health policy shaped by patient experience.

New pediatric guidelines standardize radiation for metastatic rhabdomyosarcoma, detailing site-specific dosing to improve STS outcomes.

Endometriosis increases ovarian cancer risk, but endometriosis-associated ovarian cancer shows favorable tumor characteristics and better survival.

Community pharmacists must build scalable workflows as bispecific antibodies move into earlier lines and outpatient settings, notes Brooke Peters, PharmD, BCOP, of AON.

The FDA announcement seeks nominees from the public for drug repurposing, leveraging AI signals to expand treatment options for rare diseases and other unmet needs.

Deep learning model beats breast density for 5-year breast cancer risk, informing supplemental screening decisions and personalized care.

Epcoritamab added to R2 sharply boosts follicular lymphoma responses, but infection risks and real-world feasibility raise tough treatment decisions.

New review maps how endometriosis hijacks glucose, lipid, and amino acid metabolism to fuel lesion survival, immune evasion, and infertility.

Health-system specialty pharmacies leverage EHR insights to enhance real-world evidence, improve access, and streamline prior authorizations.

New soft tissue sarcoma radiotherapy guidelines favor preoperative radiotherapy, refine dosing and targeting, and preview the role of immunotherapy and hypofractionation.

Amid breast cancer surging in women under 50, new data and WISDOM trial results support individualized screening over age-based guidelines.

Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance.

Rani Bansal, MD, discusses breast cancer subtypes, racial disparities in triple-negative disease, self-advocacy for young patients, and diversity in clinical trials.